echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Phase I clinical study of Sansheng Guojian anti-IL-1β monoclonal antibody completed the first subject enrollment

    The Phase I clinical study of Sansheng Guojian anti-IL-1β monoclonal antibody completed the first subject enrollment

    • Last Update: 2021-08-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 19, Sansheng Guojian announced that the company's new recombinant humanized anti-IL-1β humanized monoclonal antibody injection (SSGJ-613) has completed the first phase I clinical study in healthy subjects


    This study is a phase I clinical study evaluating the safety, tolerability and pharmacokinetic characteristics of a randomized, double-blind, placebo-controlled single subcutaneous injection of SSGJ-613 in healthy subjects


    IL-1β belongs to the IL-1 family


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.